AI and Rare Diseases ── 2026-11-20

New papers on rare diseases (other than neurological and cancer) and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 8 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Platforms(1) · Inborn errors of metabolism(0) · Genetic syndromes(0) · Rare blood disorders(0) · Immune and connective tissue(0) · Heart and lung(1) · Kidney, liver and gut(0) · Skin and bone(0)
Rare-disease diagnosis and drug discovery platforms and AI
- Abstract
BACKGROUND: Kawasaki Disease (KD) is an acute, self-limited vasculitis of childhood, with its etiopathogenesis intricately tied to systemic inflammation and endothelial dysfunction. Disruption of circadian rhythms and mitochondrial transport, 2 fundamental homeostatic systems, are increasingly recognized as independent contributors to vascular pathology. However, their integrated molecular crosstalk in KD remains completely uncharted. OBJECTIVE: The primary objective was to identify and validate a mitochondrial transport andcircadian rhythm (MRC)-related molecular signature in KD. The secondary objectives were to resolve MRC-defined molecular subtypes, to nominate and characterize a candidate hub gene, to define its cellular distribution, and to prioritize candidate therapeutic compounds. METHODS: First, Peripheral blood bulk transcriptomic datasets of KD patients were analyzed. GSE68004 was interrogated via Limma, GSVA, and WGCNA to isolate MRC-associated shared DEGs. Second, non-negative matrix factorization (NMF) and 3 machine learning algorithms (RF, Lasso and SVM-RFE) were deployed in GSE63881 for molecular subtype identification and diagnostic model construction, with independent diagnostic validation in integrated GSE73463 and GSE73462. Next, leveraging single-cell transcriptomic data from peripheral blood samples of KD patients (GSE24757), we resolved the spatiotemporal dissemination and functional evolution of the hub gene. In addition, deep learning-driven drug screening (DrugReflector) and molecular docking nominated a candidate compound in GSE18606. Finally, differential expression of the hub gene was validated using q-RT-PCR in clinical samples from KD patients. RESULTS: The integrated MRC-related signature robustly stratified KD patients into 2 distinct molecular subgroups. FNDC5 was identified as an NK-distributed and MRC-related pathogenic factor in KD. BRD-K10482608 was nominated as a computationally predicted candidate targeting FNDC5 for KD. CONCLUSION: This study provides the first pathway-anchored MRC-related signature in KD together with a validated framework for molecular stratification. FNDC5 is put forward as a prioritized, hypothesis-generating candidate of KD vasculopathy, and BRD-K10482608 as a computationally nominated starting point for future functional and nursing pharmacological testing.
Journal IF-equivalent: 4.1 (OpenAlex 2-year mean citedness, value as of 2026-11-19, retrieved 2026-11-20; not the official Clarivate IF)Reference: Yang Y. Deciphering mitochondrial dysfunction and circadian rhythm-related pathogenic patterns for the pathogenesis of Kawasaki Disease and corresponding nursing therapeutic enrichment: Evidence from machine learning-driven multi-omics and clinical validation. Computational Biology and Chemistry. 2027 Feb;126:109575. doi:10.1016/j.compbiolchem.2026.109575.Checked: Abstract only
Inborn errors of metabolism: treatment, trials and AI
No new qualifying paper for this issue.
Genetic syndromes and paediatric rare diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare blood disorders: treatment, trials and AI
No new qualifying paper for this issue.
Autoinflammatory, immunodeficiency and rare connective-tissue diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare cardiovascular and respiratory diseases: treatment, trials and AI
- Abstract
BACKGROUND: Females are under-represented in cardiac amyloidosis (CA), but whether this reflects sex-associated phenotypic heterogeneity or differences in disease prevalence remains unclear. OBJECTIVES: The objectives of the study was to characterize sex-associated differences in presentation and prognosis across CA subtypes using unsupervised clustering. METHODS: We retrospectively analyzed 2,216 patients with confirmed CA enrolled between 2010 and 2022: light-chain amyloidosis (AL) (n = 583), variant transthyretin amyloidosis (ATTRv) (n = 432), and wild-type transthyretin amyloidosis (ATTRwt) (n = 1,201). Self-organizing maps with k-means partitioning were applied separately to each subtype, and conditional inference trees identified key phenotypic discriminators. RESULTS: Females represented 40.8%, 33.8%, and 15.9% of AL, ATTRv, and ATTRwt cohorts, respectively. Clustering identified 4 AL, 6 ATTRv, and 6 ATTRwt phenotypes. Across subtypes, female-predominant clusters generally showed preserved left ventricular ejection fraction, lower cardiac remodeling burden, and less pronounced biomarker elevation. Female-predominant AL clusters included preserved-function and multisystem profiles, whereas ATTRv clusters included neurologic-dominant and older cardiometabolic profiles. In ATTRwt, females were predominantly represented in a phenotype characterized by preserved systolic function and less structural remodeling. Conditional inference trees identified sex as the first discriminator in ATTRwt and a secondary discriminator in AL, whereas ATTRv clusters were primarily discriminated by cardiac variables and sex was not selected. CONCLUSIONS: Unsupervised clustering identified female-predominant phenotypes with less structural cardiac remodeling but distinct multisystem characteristics across CA subtypes. These findings support sex-associated phenotypic heterogeneity in CA and generate hypotheses regarding female underrepresentation in contemporary CA cohorts.
Journal IF-equivalent: 3.7 (OpenAlex 2-year mean citedness, value as of 2026-11-19, retrieved 2026-11-20; not the official Clarivate IF)Reference: Zaroui A, Lafont C, Kharoubi M, Riccardi B, Teiger E, Itti E, et al. Sex-Specific Phenotypic Architecture in Cardiac Amyloidosis Identified by Explainable Machine Learning. JACC: Advances. 2026 Dec;5(12):103480. doi:10.1016/j.jacadv.2026.103480.Checked: Abstract only
See all 1 Heart and lung papers →
Rare kidney, liver and gastrointestinal diseases: treatment, trials and AI
No new qualifying paper for this issue.
Rare skin and bone diseases: treatment, trials and AI
No new qualifying paper for this issue.